Extended Data Fig. 8: Partial depletion of hepatic cDC1 infiltration using anti-XCL1 antibody in CDHFD-fed mice attenuates NASH progression.

a, Levels of liver enzymes ALT and AST in the serum of wild type CDHFD-fed mice before anti-XCL1 or IgG isotype control treatment. b, Quantification of CD103 + MHC-II + CD11c + cells from 5–10 randomly selected areas per mouse c, Levels of AST, a measure of tissue injury, including liver, in the serum of wild type mice before feeding with CDHFD (grey), after 5 months of CDHFD but before treatment (black), and following 4 weeks of anti-XCL1 or control IgG treatment (blue). In a-c n = 6–7 per group. Data are presented as mean ± s.e.m. P-values were determined by two-way ANOVA with Tukey’s multiple comparisons test; ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 d,e, Representative pictures of H&E staining (d) and pathological evaluation of NAFLD activity score (e) in anti-XCL1 or IgG isotype control-treated, CDHFD-fed mice. Images representative for two experiments. f,g, Representative pictures (f) and quantification (g) of Sirius Red staining in anti-XCL1 or IgG isotype control-treated, CDHFD-fed mice. Images representative for two independent experiments. In e, g, data are presented as mean ± s.e.m.; n = 7 per group, two-tailed Student’s t-test h. Correlation analysis between MHC-II⁺CD11c⁺CD103⁺ cDC1 count and NASH pathology parameters in anti-XCL1-treated and IgG-treated mice. n = 14 mice, two-tailed Spearman correlation (crossed out points p > 0.05; color and circle size indicate R2).